antisens
technolog
present
opportun
manipul
gene
express
within
cell
treat
endless
number
diseas
power
tool
studi
gene
function
antisens
approach
util
antisens
agent
fight
variou
diseas
regul
express
specif
factor
presenc
actual
caus
particular
diseas
antisens
approach
evolv
last
decad
explicitli
introduct
antisens
oligonucleotid
odn
stephenson
zamecnik
late
descript
ribozym
cech
colleagu
demonstr
short
interf
rna
sirna
fire
mello
recent
microrna
mirna
replac
therapi
emerg
new
approach
treat
human
diseas
like
cancer
variou
neurodegen
diseas
replac
therapi
involv
reintroduct
synthet
version
natur
mirna
get
deplet
diseas
tissu
highli
specif
effect
gene
silenc
diseas
achiev
accur
knowledg
target
mrna
sequenc
ration
design
complementari
antisens
agent
downregul
protein
messag
thu
extens
explor
person
therapi
cancer
hiv
mutat
viral
diseas
gene
silenc
also
great
potenti
chemosensit
agent
overcom
difficulti
drug
resist
doselimit
toxic
chemotherapeut
agent
techniqu
differ
use
convent
drug
precis
check
format
diseasecaus
protein
downregul
express
rather
reliev
symptom
diseas
manifest
moreov
techniqu
differenti
genet
approach
action
mrna
express
diseasecaus
protein
rather
act
particular
faulti
gene
success
approach
reli
understand
correct
sequenc
rna
carri
protein
messag
respons
diseas
interest
fortun
complet
human
genom
project
endow
us
rich
sourc
inform
target
gene
ration
design
antisens
drug
within
hour
research
clinic
trial
sinc
discoveri
antisens
technolog
continu
progress
rapidli
section
review
knowledg
antisens
drug
deliveri
discoveri
applic
discov
late
express
specif
gene
product
could
inhibit
use
short
complementari
dna
sequenc
led
intens
research
antisens
approach
concept
antisens
techniqu
came
view
discoveri
singlestrand
dna
molecul
known
antisens
oligodeoxynucleotid
odn
zamecnik
stephenson
sinc
new
applic
antisens
technolog
continu
develop
rapidli
earli
development
stage
blockag
target
protein
express
achiev
administ
whole
dna
rna
local
therapeut
singlestrand
dna
molecul
odn
first
local
administ
treatment
howev
mechan
antitumor
activ
never
elucid
activ
also
vari
size
structur
compar
studi
done
dna
extens
research
report
use
rna
polyribonucleotid
medicin
agent
earli
stage
develop
doublestrand
polyriboinosinepolyribonocytidin
extens
studi
polynucleotid
miller
et
al
first
tri
modifi
phosphat
backbon
oligonucleotid
improv
properti
synthes
first
chemic
modifi
oligonucleotid
belong
class
methyl
phosphotriest
oligonucleotid
thereaft
ribozym
anoth
class
catalyt
oligonucleotid
appear
new
tool
investig
gene
express
depend
structur
ribozym
degrad
modifi
target
mrna
produc
correct
sequenc
odn
ribozym
alreadi
clinic
practic
genet
therapeut
long
small
interf
rna
sirna
develop
potenti
medicin
agent
fire
et
al
first
describ
rnai
mechan
action
odn
destruct
target
mrna
natur
cellular
defens
mechan
virtu
presenc
doublestrand
viral
dna
trigger
mrna
degrad
introduct
sirna
could
exhibit
antivir
activ
block
express
viral
protein
led
progress
sirna
therapeut
block
product
diseaserel
protein
present
three
decad
emerg
antisens
concept
basic
technolog
key
step
challeng
therapeut
well
comprehens
main
attent
research
pharmaceut
industri
today
make
technolog
avail
therapeut
applic
thu
today
focu
design
antisens
molecul
good
affin
specif
predict
vivo
effect
also
practic
approach
formul
take
care
ultim
pharmacolog
toxicolog
aspect
initi
stage
develop
avoid
reject
final
clinic
phase
incred
progress
made
ration
design
appropri
select
antisens
agent
formul
deliveri
carrier
dose
dosag
regimen
importantli
design
preclin
clinic
trial
sinc
discoveri
antisens
technolog
numer
advanc
structur
properti
oligonucleotid
use
therapeut
agent
compar
whole
dna
rna
today
rnai
achiev
use
sirna
dsrna
doublestrand
rna
shrna
short
hairpin
rna
sever
modif
novel
base
sugar
conjug
chimer
technolog
tri
improv
pharmacokinet
pharmacodynam
properti
oligonucleotid
biolog
activ
odn
site
action
depend
factor
concentr
concentr
mrna
rate
synthesi
degrad
mrna
type
termin
mechan
variou
strategi
employ
improv
properti
system
administ
oligonucleotid
potent
gene
therapi
ribozym
gain
attent
odn
ribozym
enzym
cleav
singlestrand
region
rna
transesterif
hydrolysi
phosphodiest
bond
achiev
rnai
either
ribozymeencod
sequenc
incorpor
plasmid
chemic
modifi
minimum
ribozym
structur
administ
chemic
modif
also
tri
synthes
nucleaseresist
ribozym
drug
moreov
earlier
use
odn
exhibit
gene
silenc
enter
nucleu
newer
one
sirna
need
enter
nucleu
lead
posttranscript
gene
silenc
degrad
target
mrna
cytoplasm
make
deliveri
challeng
littl
simpler
odn
evolut
differ
antisens
technolog
close
path
oglionucelotid
rather
progress
improv
oligonucleotid
hasten
pace
newer
antisens
agent
reach
therapeut
platform
current
swift
progress
systemat
research
develop
obviat
downsid
face
previous
odn
earlier
growth
clinic
step
downregul
mrna
express
made
possibl
either
via
transcript
arrest
rna
complementari
diseaserel
protein
posttranscript
gene
silenc
ptg
phenomenon
transcript
arrest
altern
inhibit
mrna
express
odn
posttranscript
transcript
arrest
doublestrand
dna
achiev
two
distinct
strategi
name
strand
invas
triplestrand
format
recent
triplestrand
format
commonli
use
strategi
induc
transcript
arrest
tripl
strand
form
involv
watsoncrick
hydrogen
bond
third
strand
complementari
strand
dna
duplex
homopyrimidin
oligonucleotid
capabl
inhibit
transcript
via
triplestrand
format
sever
modif
oligonucleotid
tri
improv
bind
duplex
dna
via
triplex
format
high
affin
specif
strand
invas
though
wide
studi
strategi
induc
transcript
arrest
use
certain
oligonucleotid
peptid
nucleic
acid
pna
inhibit
transcript
ptg
phenomenon
antisens
agent
act
degrad
transcrib
target
mrna
prevent
translat
complementari
protein
fig
antisens
molecul
lead
manipul
andor
modif
dna
rna
number
differ
mechan
partial
complet
elimin
normal
cellular
process
genet
messag
gene
accomplish
knockdown
knockout
major
challeng
present
antisens
techniqu
achiev
clinic
approv
statu
essenti
better
understand
variou
pharmaceut
pharmacolog
consider
avail
activ
moieti
act
desir
site
therapeut
effect
concentr
formul
appropri
dosag
form
differ
barrier
reach
target
interest
though
antisens
technolog
hold
great
therapeut
potenti
sever
barrier
fig
often
imped
deliveri
odn
sirna
site
action
barrier
encount
nake
oligonucleotid
sirna
differ
encount
one
associ
variou
nanocarri
elicit
pharmacolog
respons
antisens
agent
must
reach
tissu
action
gener
circul
invad
diseas
cell
interact
complementari
mrna
follow
endosom
releas
therebi
inhibit
express
desir
protein
howev
larg
size
ionic
natur
oligonucleotid
sirna
imped
effici
travers
variou
biolog
membran
discuss
variou
barrier
encount
administ
odn
also
studi
extens
sirna
possibl
way
overcom
barrier
effici
deliveri
ultim
target
action
odn
sirna
thu
barrier
challeng
remedi
discuss
one
appli
less
travel
site
administr
site
action
antisens
agent
cross
variou
physiolog
enzym
compart
affect
extent
effici
deliveri
target
follow
administr
first
biolog
barrier
oligonucleotid
face
present
nucleas
activ
blood
tissu
within
min
nearli
administ
antisens
molecul
degrad
result
low
gene
silenc
chemic
modif
use
nonvir
vector
drastic
improv
stabil
oligonucleotid
toward
nucleas
biolog
system
remark
modif
done
posit
pentos
sugar
half
sirna
structur
substitut
sulfur
oxygen
form
phosphorothio
oligonucleotid
common
chemic
modif
improv
stabil
toward
nucleas
modif
lock
nucleic
acid
lna
pna
morpholino
compound
hexitol
nucleic
acid
hna
also
improv
mrna
stabil
toward
nucleas
addit
prolong
pharmacolog
action
observ
inclus
sixcarbon
sugar
instead
ribos
modif
use
gapmer
similarli
cation
lipid
polym
readili
complex
anion
antisens
molecul
electrostat
interact
therebi
protect
oligonucleotid
degrad
nucleas
follow
administr
gener
circul
oligonucleotidesor
specif
oligonucleotid
associ
nanocarri
size
greater
nmare
subject
phagocytosi
matur
macrophag
resid
tissu
reticuloendotheli
system
re
liver
spleen
lung
nevertheless
particl
smaller
nm
leak
intercellular
junction
capillari
endothelium
interstiti
space
hepat
sinusoid
hepat
uptak
get
trap
hepat
kupffer
cell
colloid
complex
odn
sirna
polym
lipid
highcharg
densiti
get
destabil
aggreg
due
presenc
neg
charg
serum
protein
size
charg
complex
determin
clearanc
circul
coat
polyethylen
glycol
peg
help
make
nanocarri
complex
long
circul
neutral
surfac
charg
impart
protect
hydrophil
sheath
around
thu
hepat
clearanc
re
uptak
nanocarrierassoci
antisens
agent
avoid
care
monitor
size
charg
final
complex
around
nm
near
neutral
respect
avoid
opson
larg
uptak
antisens
agent
tissu
fenestr
vasculatur
liver
spleen
benefici
target
molecul
tissu
also
oligonucleotid
smaller
nm
kd
molecular
weight
undergo
rapid
clearanc
bodi
glomerular
filtrat
glomerular
filtrat
avoid
manipul
size
antisens
molecul
incorpor
suitabl
nanocarri
system
attach
target
ligand
endotheli
cell
line
vascular
lumen
present
barrier
odnbas
therapi
oligonucleotid
need
cross
endothelium
deliv
tissu
parenchym
cell
endotheli
cell
tightli
adher
underli
extracellular
matrix
via
integrin
via
sever
adhes
molecul
form
tight
intercellular
junction
small
intercellular
space
small
oligonucleotid
travel
across
endothelium
via
paracellular
rout
involv
imperfect
intercellular
junction
howev
certain
tissu
liver
spleen
endotheli
intercellular
space
rel
larger
bodi
tissu
allow
access
even
larg
oligonucleotid
odn
also
travers
across
endotheli
cell
transcellularli
via
claveolinbas
transcytosi
transcellular
transport
size
independ
allow
passag
small
larg
oligonucleotid
molecul
cellpenetr
peptid
target
ligand
molecular
conjug
use
facilit
passag
odn
across
endotheli
line
exert
action
antisens
agent
need
enter
cell
reach
actual
target
face
follow
challeng
nonvir
vectora
odn
complex
highli
cation
bind
nonspecif
neg
charg
cell
membran
easili
taken
cell
re
endocytosi
membran
fusion
nonspecif
cellular
uptak
nontarget
tissu
result
sever
toxic
manifest
due
unwant
protein
express
nonspecif
cellular
uptak
reduc
coat
nonvir
vectora
odn
complex
peg
attach
cellspecif
target
ligand
transferrin
folat
surfac
receptorspecif
antibodi
coupl
membraneperm
peptid
like
transportan
penetratin
also
enhanc
cellular
intern
coat
peg
reduc
uptak
re
also
reduc
uptak
target
cell
henc
ration
use
cellspecif
target
ligand
along
peg
coat
howev
use
receptorspecif
antibodi
evok
immunogen
manifest
therefor
antibodi
must
suitabl
tailor
use
target
ligand
odn
reach
target
cell
escap
pericellular
vesicl
endosom
lysosom
requir
transfect
henc
transfect
effici
nonvir
vector
depend
cellular
intern
well
endosom
escap
activ
moieti
reach
actual
target
two
strategi
wide
use
enhanc
endosom
escap
first
use
fusogen
lipid
peptid
ruptur
lysosom
membran
form
pore
membran
phsensit
liposom
system
lipofectin
compos
cation
lipid
along
fusogen
helper
lipid
dope
report
readili
releas
entrap
oligonucleotid
lowph
environ
interact
cation
lipid
liposom
anion
lipid
cell
membran
endosom
membran
result
phase
separ
therebi
creat
doperich
region
form
pore
membran
caus
membran
destabil
second
strategi
involv
use
deliveri
system
possess
high
buffer
capac
prevent
acidif
endosom
result
disrupt
endosom
membran
polyethylenimin
use
buffer
agent
polymera
odn
complex
also
endoosmolyt
agent
like
chloroquin
higher
concentr
osmot
agent
like
glycerol
sucros
polyvinyl
pyrrolidon
pvp
shown
aid
osmolysi
endosom
follow
endosom
escap
releas
cation
complex
sirna
cytoplasm
nuclear
local
odn
requir
interact
target
mrna
inhibit
relat
protein
express
addit
anion
lipid
displac
neg
charg
sirna
odn
cation
lipidpolymeroligonucleotid
complex
releas
attribut
multival
natur
anion
lipid
electrostat
hydrophilichydrophob
interact
lipid
lipid
mix
result
charg
neutral
allow
diffus
cation
lipid
away
oligonucleotid
thu
anion
lipid
compet
anion
oligonucleotid
cation
lipid
displac
oligonucleotid
cation
polymera
odn
complex
cation
polym
like
polyethyleneimin
pei
polyllysin
pll
acceler
nuclear
local
prevent
cytosol
degrad
complex
extent
durat
oligonucleotid
respons
depend
upon
step
limit
rate
cellular
uptak
intracellular
traffick
endosom
releas
nuclear
entri
step
control
conjug
cellpenetr
signal
peptid
endosom
releas
signal
peptid
nuclear
local
signal
peptid
oligonucleotid
howev
sirna
polyplex
reduc
polym
polyethyleneglycolpolyllysin
pegpll
block
copolym
disulfid
crosslink
prefer
cytosolspecif
degrad
releas
sirna
cytoplasm
act
target
mrna
cytosol
nuclear
local
odn
must
bind
complementari
mrna
therebi
downregul
relat
protein
express
transfect
effici
cation
lipidpolymeroligonucleotid
complex
depend
lipidpolymertooligonucleotid
ratio
henc
lipidpolymertooligonucleotid
ratio
must
optim
achiev
maximum
inhibit
mrna
express
inclus
tissuespecif
promot
tri
inhibit
mrna
express
within
therapeut
window
formul
appropri
concentr
decid
sound
understand
pharmacokinet
biodistribut
particular
antisens
molecul
appropri
modif
overcom
undesir
barrier
provid
valu
antisens
therapeut
bodi
inbuilt
mechan
fight
invad
foreign
bodi
pathogen
resist
confer
two
distinct
mechan
name
innat
immun
adapt
immun
present
major
barrier
intracellular
odn
deliveri
individu
born
innat
immun
mediat
receptor
bind
conserv
structur
call
pathogenassoci
molecular
pattern
pamp
common
mani
pathogen
thu
innat
immun
major
concern
case
viral
vectorbas
antisens
drug
deliveri
hand
adapt
immun
individu
acquir
birth
exposur
diseasecaus
pathogen
mediat
b
lymphocyt
pathogen
invad
bodi
interact
specif
surfac
receptor
b
lymphocyt
caus
activ
product
effector
cell
antibodi
neutral
pathogen
mani
research
report
danger
immun
respons
odn
phosphorothio
administ
monkey
larg
onetim
inject
trigger
system
lethal
inflamm
activ
complement
also
stimul
dramat
increas
immunoglobulin
secret
within
h
increas
express
activ
marker
mhc
class
ii
cpg
cytosin
guanin
separ
phosphatecontain
phosphorothio
augment
natur
killer
nk
cell
activ
modul
cell
function
may
stimul
releas
sever
member
interleukin
famili
odn
bind
specif
mrna
therebi
downregul
express
encod
protein
howev
mechan
oligonucleotid
interact
complementari
mrna
induc
biolog
effect
complex
difficult
elucid
complet
ultim
goal
antisens
agent
suppress
complet
block
product
relat
gene
product
mean
process
transit
dna
sequenc
amino
acid
sequenc
normal
transcript
translat
apparatu
must
affect
format
protein
product
involv
three
distinct
step
fig
first
step
sens
strand
dna
transcrib
premrna
second
premrna
convert
matur
mrna
via
simultan
action
three
separ
process
viz
cap
intron
excis
polyadenyl
final
third
step
mrna
transport
ribosom
translat
appropri
polypeptid
thu
antisens
drug
act
inhibit
step
involv
normal
protein
product
although
activ
rnase
h
enzym
activ
thought
mechan
action
major
odn
mani
still
exert
biolog
effect
via
report
mechan
next
discuss
mechan
detail
rnase
h
endogen
enzym
cleav
rna
strand
rnadna
duplex
wide
use
valid
mechan
knockdown
mrna
result
reduct
mrna
protein
express
howev
precis
mechan
rnase
h
enzym
recogn
duplex
elucid
complet
rnase
h
cleavag
site
found
near
translat
initi
codon
untransl
region
rnase
h
found
nucleu
cytoplasm
cell
regular
function
remov
rna
primer
okazaki
fragment
dna
replic
henc
oligonucleotid
act
via
rnase
h
activ
must
design
care
although
requir
odn
inhibit
protein
express
known
precis
modif
sugar
moieti
sugar
type
orient
thought
influenc
rnase
h
activ
modif
result
dnalik
oligonucleotid
support
rnase
h
activ
chang
result
rnalik
oligonucleotid
support
rnase
h
activ
modif
oligonucleotid
backbon
also
alter
rnase
h
activ
howev
favor
design
use
chimer
molecul
singl
ribonucleotid
bound
complementari
oligonucleotid
backbon
serv
substrat
rnase
h
rnase
hdepend
oligonucleotid
inhibit
protein
express
bind
region
complementari
mrna
cap
essenti
step
protein
synthesi
cascad
stabil
translat
mrna
matur
polypeptid
sequenc
although
effect
mechan
inhibit
mrna
translat
establish
mechan
action
odn
due
inaccess
end
mrna
cap
lone
except
far
valid
morpholinooligonucleotid
place
near
end
mrna
morpholinooligonucleotid
shown
specif
reduc
translat
splice
import
specif
step
translat
mrna
protein
requir
spliceosom
odn
act
bind
specif
splice
sequenc
mrna
therebi
inhibit
translat
product
relat
protein
phosphorothio
oligonucleotid
report
inhibit
protein
express
inhibit
splice
mani
odn
bind
translat
initi
codon
therebi
induc
translat
arrest
pna
morpholinooligonucleotid
report
act
via
translat
arrest
bind
translat
initi
codon
translat
arrest
report
mechan
action
inhibit
replic
virus
like
hiv
vesicular
stomat
viru
polyadenyl
intermedi
step
protein
synthesi
requir
addit
long
tract
polyadenyl
premrna
molecul
therebi
stabil
cap
premrna
could
inhibit
polyadenyl
destabil
howev
date
studi
report
polyadenyl
mechan
action
antisens
drug
mechan
involv
physic
blockag
rna
therebi
prevent
protein
express
rnadna
duplex
format
achiev
bind
end
translat
initi
codon
mrna
rnaprocess
event
nuclear
splice
polyadenyl
also
inhibit
steric
blockad
mrna
pna
morpholinooligonucleotid
report
inhibit
mrna
translat
steric
blockad
odn
inhibit
mrna
translat
activ
doublestrand
rnase
enzym
call
dicer
therebi
cleav
dsrna
rnai
antisens
mechan
action
util
enzym
dicer
promot
hydrolysi
target
rna
sirna
oligonucleotid
duplex
report
inhibit
protein
express
rnai
pathway
activ
doublestrand
rnase
potenc
maxim
effect
durat
action
sequenc
specif
sirna
oligonucleotid
duplex
found
compar
rnase
hdepend
oligonucleotid
also
activ
sirna
oligonucleotid
found
affect
secondari
structur
target
mrna
rnai
pathway
fig
involv
sever
complic
step
discuss
brief
process
rnai
activ
exposur
dsrna
precursor
initi
step
presenc
atp
rnaseiiityp
endonucleas
dsrna
precursor
process
smaller
nucleotid
call
sirna
length
nucleotid
result
sirna
subsequ
incorpor
multiprotein
complex
known
rnainduc
silenc
complex
risc
success
step
presenc
atp
sirna
molecul
undergo
unwind
aid
helicas
get
process
risc
activ
complex
leav
antisens
strand
sirna
associ
risc
sens
strand
get
degrad
exoribonucleas
cytoplasm
activ
risc
direct
sirna
toward
complementari
mrna
sequenc
bind
sirna
complementari
mrna
sequenc
risc
complex
cleav
target
mrna
help
argonaut
enzym
associ
risc
cleav
mrna
degrad
nucleas
cytoplasm
therebi
inhibit
express
relat
protein
freed
risc
complex
recycl
cleav
target
mrna
sequenc
date
broad
array
diseas
target
explor
util
variou
antisens
agent
odn
ribozym
aptam
sirna
avail
techniqu
achiev
suppress
elimin
genet
messag
relat
particular
diseas
oligonucleotidebas
antisens
techniqu
repres
first
clinic
success
approach
target
ocular
diseas
none
antisens
agent
becom
avail
system
applic
odn
sirna
larg
ionic
structur
similar
natur
nucleic
acid
use
per
se
genet
medicin
henc
serv
effect
drug
must
possess
desir
pharmacokinet
pharmacodynam
properti
vari
oligonucleotid
length
sequenc
chemic
class
variou
modif
basic
structur
odn
tri
improv
properti
reduc
toxic
maintain
target
specif
impart
resist
nucleas
elicit
biolog
respons
odn
must
absorb
site
administr
distribut
variou
tissu
maximum
uptak
target
cell
resist
chemic
enzymat
degrad
amend
protect
nucleas
maintain
desir
characterist
antisens
effect
introduc
dna
well
rna
nucleotid
fig
alter
base
modif
phosphat
backbon
group
also
tailor
rna
nucleotid
synthet
modifi
odn
group
three
broad
categori
viz
first
second
thirdgener
odn
includ
phosphorothio
oligonucleotid
fig
synthes
replac
one
nonbridg
oxygen
atom
phosphat
backbon
sulfur
atom
methylphosphon
prepar
replac
nonbridg
oxygen
atom
methyl
group
phosphoru
oligonucleotid
chain
methylphosphon
neutral
excel
stabil
biolog
milieu
activ
rnase
h
activ
cellular
uptak
occur
adsorpt
endocytosi
membran
diffus
phosphorothio
oligonucleotid
wide
studi
oligonucleotid
first
synthes
chemic
modif
primarili
tri
improv
stabil
odn
toward
nucleas
phosphorothio
oligonucleotid
found
cytotox
high
concentr
bind
nonspecif
certain
protein
induc
antisens
effect
rnase
hdepend
mechan
phosphorothio
oligonucleotid
halflif
h
human
serum
compar
h
unmodifi
oligonucleotid
sequenc
taken
receptormedi
endocytosi
cell
howev
due
neg
associ
firstgener
odn
larg
size
chemic
enzymat
instabl
secondand
thirdgener
odn
develop
includ
rna
oligonucleotid
alkyl
modif
posit
ribos
sugar
rna
omerna
rna
moerna
synthes
replac
group
methyl
methoxyethyl
group
respect
fig
oligonucleotid
design
address
issu
like
nonspecif
protein
bind
cytotox
associ
phosphorothio
odn
resist
nucleas
phosphorothio
howev
major
drawback
associ
oligonucleotid
poor
elimin
properti
rnase
hindepend
antisens
mechan
action
agent
effect
steric
blockad
mechan
includ
gapmer
odn
like
pna
lna
phosphoroamid
pa
hna
nucleic
acid
cyclohexen
nucleic
acid
cage
nucleic
acid
other
shown
fig
gapmer
contain
central
block
deoxynucleotid
suffici
induc
rnase
h
cleavag
flank
block
ribonucleotid
protect
intern
block
nucleas
degrad
odn
increas
thermal
stabil
hybrid
enhanc
target
recognit
support
rnase
h
activ
also
compar
less
toxic
firstor
secondgener
oligonucleotid
show
low
interact
plasma
protein
one
earliest
studi
thirdgener
construct
antisens
pna
pna
odn
sugar
phosphat
backbon
replac
complet
polyamid
linkag
compris
repeat
n
glycin
unit
attach
nucleobas
via
methylen
carbonyl
linker
possess
increas
stabil
favor
hybrid
due
absenc
neg
charg
pna
oligom
support
rnase
h
antisens
mechan
exert
antisens
effect
steric
blockad
bind
rna
transcript
factor
pa
morpholinooligonucleotid
synthes
substitut
deoxyribos
moieti
morpholino
ring
charg
phosphodiest
linkag
neutral
pa
linkag
biolog
stabl
possess
effici
antisens
activ
rnase
h
independ
compar
less
toxic
firstor
secondgener
oligonucleotid
show
low
interact
plasma
protein
lna
new
promis
thirdgener
modif
compos
nucleotid
lock
singl
conform
via
methylen
linkag
possess
remark
increas
thermodynam
stabil
enhanc
nucleic
acid
recognit
decad
appear
odn
anoth
enzymat
molecul
call
ribozym
describ
tetrahymena
thermophilia
antisens
agent
ribozym
rna
enzym
potenti
process
rna
thu
act
knock
gene
express
hammerhead
ribozym
explor
extens
catalyt
effici
due
catalyt
core
structur
sequencespecif
bind
capac
rna
due
two
flank
sequenc
structur
hammerhead
ribozym
two
region
catalyt
core
cleavag
two
flank
sequenc
confirm
bind
specif
shorter
flank
sequenc
nucleotid
present
rapid
turnov
rate
ribozym
lead
activ
rnase
degrad
dsrna
recognit
mani
ribozym
formul
differ
phase
clinic
trial
tabl
aptam
consid
chemic
antibodi
properti
nucleotidebas
therapi
use
knock
express
target
extracellular
well
cytoplasm
protein
aptam
short
stretch
rna
dna
specif
threedimension
structur
form
complex
target
protein
inhibit
express
block
activ
essenti
aptam
complementari
target
mrna
instead
threedimension
tertiari
quaternari
structur
determin
specif
bind
capabl
aptam
well
util
nonimmunogen
altern
antibodi
even
time
higher
dose
aptam
acquiesc
amend
appli
nucleotidebas
antisens
agent
thu
aptam
tailor
accord
variou
requir
modif
safeguard
structur
specif
bind
region
sirna
long
dsrna
trigger
cellular
rnai
degrad
complementari
mrna
cytoplasm
requir
sequencespecif
translat
arrest
sirna
oligonucleotid
extens
explor
therapeut
target
pro
con
although
similar
sens
act
antisens
differ
mani
aspect
tabl
rnai
potent
antisens
gener
make
select
candid
sequenc
much
easier
mammalian
cell
singlestrand
rna
introduct
viral
long
dsrna
nt
trigger
rnai
initi
potent
antivir
respons
inhibit
protein
synthesi
mrna
degrad
natur
defens
mechan
util
antisens
technolog
fight
tremend
number
diseas
introduct
express
sirna
presenc
long
dsrna
trigger
rnai
pathway
lead
activ
dicer
enzym
cut
long
dsrna
short
rna
fragment
call
sirna
sirna
fragment
degrad
complementari
mrna
prevent
express
undesir
protein
sirna
produc
chemic
well
enzymat
introduc
directli
cell
without
minim
interferon
respons
compar
long
dsrna
sinc
mani
studi
execut
evalu
therapeut
potenti
sirna
pharmaceut
industri
invest
billion
technolog
licens
deliveri
platform
strateg
allianc
develop
rnaibas
therapeut
product
initi
studi
limit
local
administr
sirna
mechan
involv
sequenti
cleavag
long
dsrna
enzym
dicer
rnase
iii
sirna
incorpor
complex
term
risc
target
degrad
mrna
transcript
either
act
dna
interfer
mrna
transcript
may
interact
mrna
sirna
specif
interfer
posttranscript
phase
perform
genesilenc
action
target
sequenc
identif
oligonucleotid
design
difficult
due
unknown
secondari
rna
structur
target
sequenc
identif
oligo
design
easier
odn
requir
higher
concentr
exert
action
gene
silenc
occur
much
lower
concentr
gene
silenc
induc
oligonucleotid
short
live
stabl
incorpor
sirna
risc
lead
prolong
gene
silenc
odn
result
less
potent
genesilenc
effect
sirna
sirna
result
significantli
greater
genesilenc
effect
lower
concentr
odn
becom
difficult
even
detect
highli
target
specif
odn
induc
mani
fewer
offtarget
effect
though
highli
target
specif
sirna
may
induc
signific
offtarget
effect
depend
length
sirna
design
odn
cross
cell
membran
compar
faster
compar
sirna
larg
molecular
mass
twice
singlestrand
odn
high
neg
charg
sirna
readili
cross
cell
membran
mostli
odn
need
enter
nucleu
effect
gene
silenc
sirna
requir
nuclear
access
exhibit
action
target
mrna
degrad
cytoplasm
increas
figur
product
clinic
preclin
stage
sign
foreseen
breakthrough
pharmaceut
biotechnolog
market
besid
sirna
short
rna
like
mirna
piwiassoci
rna
pirna
also
identifi
fold
long
singlestrand
rna
sequenc
encod
specif
gene
function
repress
mrna
translat
degrad
intramolecular
hairpin
contain
imperfectli
basepair
segment
led
format
mirna
pirna
also
long
singlestrand
precursor
function
associ
piwi
subfamili
argonaut
protein
larg
number
tini
noncod
rna
discov
sinc
continu
sirna
first
identifi
potenti
regul
gene
express
recent
mirna
shown
regul
critic
biolog
process
growth
develop
oncogenesi
hostpathogen
interact
higher
eukaryot
mirna
natur
molecul
also
consist
dsrna
short
singlestrand
end
primari
mirna
transcrib
dna
fold
hairpin
drosha
enzym
cut
hairpin
rest
transcript
form
premirna
dicer
enzym
cut
away
loop
form
matur
doublestrand
mirna
doubl
strand
load
onto
ribonucleoprotein
complex
mirnp
includ
argonaut
protein
argonaut
cleav
one
strand
dsrna
incorpor
uncleav
singl
strand
matur
complex
complex
inhibit
translat
partial
complementari
mrna
behavior
two
class
sirna
mirna
mirna
encod
genom
natur
use
cell
regul
gene
express
sirna
hand
affector
molecul
rnai
pathway
gener
cleavag
dsrna
cleav
perfectli
complementari
mrna
target
decreas
express
partial
complementari
target
howev
major
differ
endogen
sirna
mirna
tabl
seem
precursor
endogen
sirna
long
dsrna
wherea
precursor
mirna
hairpinshap
rna
endogen
silenc
small
rna
term
mirna
genet
encod
potenti
aris
foldback
structur
characterist
mirna
precursor
hairpin
sirna
similar
small
rna
appear
correspond
proteincod
region
potenti
aris
hairpin
characterist
mirna
precursor
yet
express
suffici
high
endogen
level
detect
rna
blot
theori
might
process
long
dsrna
progress
made
understand
role
mirna
biolog
milieu
therapeut
molecul
promis
target
variou
diseas
includ
variou
neurodegen
diseas
yet
effect
therapi
convent
druggabl
target
howev
tradit
antisens
novel
sirna
oligonucleotid
mirna
typic
need
chemic
modif
formul
clinic
suitabl
safe
effect
drug
deliveri
vehicl
stabil
tissu
target
achiev
essenti
understand
vivo
effect
molecul
develop
variou
sensit
analyt
method
select
quantifi
oligonucleotid
biolog
system
made
possibl
studi
metabol
compound
easili
howev
pharmacokinet
oligonucleotid
report
sequenc
independ
data
one
sequenc
use
understand
pharmacokinet
entir
class
pharmacokinet
discuss
kinet
antisens
drug
clearanc
drug
site
action
ultim
pharmacolog
activ
phosphorothio
oligonucleotid
wide
studi
discuss
odn
kinet
respect
pharmacokinet
phosphorothio
oligonucleotid
precursor
endogen
sirna
long
dsrna
precursor
mirna
hairpinshap
rna
dsrna
precursor
give
rise
numer
differ
sirna
hairpin
process
ultim
accumul
singl
mirna
molecul
one
arm
hairpin
precursor
molecul
sirna
may
endogen
exogen
deriv
virus
mirna
entir
endogen
sirna
gener
exhibit
less
sequenc
conserv
sequenc
matur
mirna
hairpin
precursor
usual
evolutionarili
conserv
sirna
synthes
rnadepend
rna
polymeras
process
dicer
enzym
mirna
synthes
rna
polymeraseii
process
drosha
dicer
enzym
main
function
sirna
cleavag
mrna
mainli
mirna
inhibit
protein
synthesi
block
mrna
translat
howev
cleavag
mrna
may
also
sirna
affect
molecul
rnai
pathway
mirna
encod
genom
regul
natur
gene
express
sirna
involv
natur
cellular
defens
mechan
mirna
regul
critic
biolog
process
growth
develop
oncogenesi
hostpathogen
interact
sirna
often
perfectli
correspond
sequenc
known
predict
mrna
transposon
region
heterochromat
dna
mirna
rare
correspond
perfectli
sequenc
mrna
target
deriv
loci
distinct
mrna
target
odn
design
specif
select
inhibit
translat
target
mrna
express
relat
protein
elucid
safeti
odn
biolog
activ
function
dose
rate
distribut
mechan
clearanc
bodi
must
establish
phosphorothio
oligonucleotid
first
synthet
prepar
antisens
nucleotid
pharmacokinet
henc
efficaci
safeti
wide
studi
report
pharmacokinet
found
independ
physic
chemic
properti
follow
inject
odn
bind
variou
protein
distribut
variou
tissu
final
get
clear
bodi
kidney
liver
organ
re
major
organ
distribut
odn
sirna
benefit
abil
target
site
certain
sirna
formul
also
accumul
subcutan
tumor
enhanc
permeabl
retent
due
leaki
vasculatur
report
data
demonstr
pattern
absorpt
distribut
clearanc
phosphorothio
variou
speci
mous
rat
dog
monkey
similar
independ
oligonucleotid
sequenc
rout
administr
intraven
administr
concentr
oligonucleotid
plasma
decreas
rapidli
distribut
half
live
min
wherea
intraven
infus
oligonucleotid
concentr
increas
linearli
dose
increas
intraven
administr
oligonucleotid
also
bypass
absorpt
barrier
antisens
drug
deliveri
usual
encount
rout
administr
howev
rapid
intraven
inject
result
hemolyt
effect
due
high
local
concentr
oligonucleotid
henc
slow
intraven
administr
advantag
rapid
inject
consid
tissu
distribut
phosphothior
ps
oligonucleotid
highest
concentr
found
liver
kidney
follow
spleen
lymph
node
tissu
uptak
oligonucleotid
readili
increas
use
longterm
continu
infus
extend
exposur
ps
oligonucleotid
target
tissu
howev
clearanc
organ
distribut
rel
slow
requir
treatment
regim
therebi
ensur
enhanc
biolog
effect
includ
metabol
excret
odn
plasma
tissu
exonucleas
account
majorli
degrad
oligonucleotid
blood
organ
distribut
respect
exonucleas
cleav
oligonucleotid
either
end
liber
smaller
nucleotid
shorten
singl
nucleotid
metabol
mani
odn
follow
pathway
endogen
nucleic
acid
immedi
follow
intraven
administr
odn
degrad
within
min
tissu
metabol
metabolit
smaller
excret
slowli
parent
oligonucleotid
lowmolecularweight
metabolit
ultim
excret
bodi
urinari
fecal
excret
howev
excret
via
bile
also
suggest
odn
ps
oligonucleotid
report
bind
readili
plasma
protein
albumin
macroglobulin
inhibit
rapid
excret
bodi
protein
bind
nonspecif
electrostat
interact
depend
salt
type
ph
surround
biolog
milieu
ps
oligonucleotid
report
bind
macroglobulin
higher
affin
albumin
oligonucleotid
also
report
bind
plasma
protein
well
lower
affin
bind
ps
oligonucleotid
thrombinbind
site
plasma
protein
result
sever
hematolog
risk
howev
protein
bind
ps
oligonucleotid
found
revers
occur
plasma
tissu
tissu
distribut
oligonucleotid
attribut
protein
bind
within
organ
cell
surfac
constitut
organ
result
higher
tissu
uptak
oligonucleotid
thu
decreas
protein
bind
oligonucleotid
result
decreas
tissu
disposit
increas
urinari
excret
certain
drug
aspirin
report
displac
ps
oligonucleotid
plasma
protein
increas
rate
excret
decreas
magnitud
biolog
effect
odn
administ
local
system
elicit
biolog
effect
local
deliveri
advantag
system
administr
avoid
distribut
nontarget
tissu
result
reduc
side
effect
associ
unwant
tissu
distribut
antisens
agent
administ
oral
nasal
rectal
vagin
pulmonari
topic
intraven
subcutan
intraderm
intrathec
rout
bioavail
ps
oligonucleotid
found
poor
follow
oral
administr
larg
size
hydrophil
ionic
natur
ps
oligonucleotid
rapidli
absorb
site
inject
follow
intraderm
subcutan
administr
follow
intrathec
pulmonari
administr
cellular
distribut
odn
account
pharmacodynam
effect
requir
suborgan
distribut
oligonucleotid
target
cell
subcellular
distribut
bind
site
target
mrna
onset
durat
antisens
activ
decid
dose
odn
frequenc
administr
dose
odn
depend
structur
chemistri
firstgener
odn
administ
three
time
week
secondgener
odn
administ
week
therapeut
effect
odn
organ
tissu
weaken
parallel
elimin
organ
tissu
nake
odn
sirna
larg
ionic
diffus
freeli
across
cell
membran
henc
facilit
entri
intracellular
target
suitabl
deliveri
system
requir
degre
biolog
effect
odn
highli
depend
deliveri
vector
use
gener
categor
viral
nonvir
vector
viral
vector
usual
better
transfect
effici
howev
nonvir
vector
found
superior
viral
vector
term
toxic
immunogen
insert
mutagenesi
discuss
vector
detail
gener
deliveri
vector
includ
cation
group
effici
load
oligonucleotid
nonion
group
steric
hindranc
endosomolyt
group
endosom
escap
target
ligand
sitespecif
deliveri
deliveri
system
suffici
larg
word
greater
nm
avoid
clearanc
glomerular
filtrat
simultan
greater
nm
avoid
leakag
interstiti
space
hepat
sinusoid
entrap
hepat
kuffer
cell
smaller
nm
avoid
uptak
organ
re
liver
spleen
thu
size
requir
system
deliveri
deliveri
system
nm
intracellular
deliveri
odn
use
viral
vector
call
transduct
viral
vector
usual
consist
viral
genom
delet
essenti
gene
transgen
insert
viral
vector
provid
high
tissu
specif
result
highli
effici
oligonucleotid
express
howev
pose
sever
safeti
risk
owe
oncogen
potenti
immunogen
effect
still
use
wide
odn
deliveri
section
discuss
commonli
employ
viral
vector
retroviru
lentiviru
herpesviru
adenoviru
adenoassoci
viru
howev
viral
vector
like
herpesviru
poxviru
also
use
carri
odn
applic
retrovirus
wide
use
rna
virus
deliv
odn
first
vector
develop
intracellular
gene
deliveri
infect
host
cell
via
help
enzym
transcriptas
requir
divid
cell
achiev
high
transduct
henc
replic
defect
vector
use
transduc
host
cell
vector
requir
integr
host
genom
result
sustain
express
vector
howev
integr
highli
nonspecif
integr
host
genom
random
posit
vector
possess
high
potenti
mutagen
consequ
possess
high
transduct
effici
carri
oligonucleotid
kb
without
express
viral
protein
lentivirus
subclass
retrovirus
henc
also
rna
virus
recent
develop
viral
vector
potenti
infect
divid
nondivid
cell
featur
uniqu
lentivirus
use
integras
enzym
transduc
host
cell
vector
also
requir
integr
host
genom
express
vector
oligonucleotid
size
kb
pack
lentivir
vector
possess
high
transduct
effici
mutagen
potenti
hivbas
lentivir
vector
success
tri
aid
adenoviru
dna
viru
commonli
use
odn
vector
replic
defici
adenovirus
delet
region
use
viral
vector
region
essenti
replic
virus
vector
infect
cell
infect
divid
nondivid
cell
possess
high
transduct
effici
carri
oligonucleotid
size
kb
retroviru
lentiviru
adenovirus
integr
host
genom
henc
replic
cell
divis
thu
vector
possess
low
mutagen
potenti
may
pose
sever
immunolog
risk
due
express
viral
protein
host
cell
follow
vector
administr
adenoassoci
viru
small
viru
infect
human
speci
requir
coinfect
either
adenoviru
herpesviru
replic
infect
divid
rest
cell
sitespecif
integr
host
genom
possess
low
mutagen
potenti
vector
incorpor
oligonucleotid
larger
kb
capabl
infect
multipl
type
cell
transfect
term
use
describ
intracellular
deliveri
antisens
agent
use
nonvir
vector
oncogen
consequ
immunolog
risk
associ
viral
vector
led
develop
novel
nonvir
vector
antisens
drug
deliveri
although
nonvir
vector
safer
viral
vector
impart
low
transient
transfect
effici
along
chemic
modif
conjug
andor
incorpor
target
ligand
like
peptid
monoclon
antibodi
essenti
achiev
desir
therapeut
effect
cation
lipidspolym
cellpenetr
peptid
commonli
use
design
deliveri
vector
tabl
posit
charg
deliveri
system
facilit
complex
neg
charg
oligonucleotid
sirna
ionic
interact
cell
membran
improv
pharmacokinet
properti
reduc
system
toxic
may
precipit
acut
immun
respons
protect
oligonucleotid
degrad
provid
control
drug
deliveri
polym
like
poli
aspart
hydrazon
adriamycin
poli
ethylen
oxid
blockpoli
aspart
acid
pluron
poli
nisopropylacrylamid
poli
ethylen
glycol
blockpoli
ethylenimin
n
methacrylamid
hpma
copolym
etc
protect
oligonucleotid
degrad
provid
control
drug
deliveri
polym
like
gelatin
chitosan
albumin
sodium
algin
poli
lactidecoglycolid
polyanhydrid
hyaluron
acid
cyclodextrin
gold
nanoparticl
silica
nanoparticl
etc
improv
pharmacokinet
properti
reduc
system
toxic
may
caus
acut
immun
respons
protect
oligonucleotid
degrad
provid
control
drug
deliveri
lipidpolym
hybrid
system
consist
hybrid
system
like
liposomeentrap
polylysinecondens
dna
lipidco
precondens
polylysinedna
poli
propylacryl
acid
coat
cation
lipiddna
conjug
etc
provid
better
protect
nucleas
effici
transfect
uncoat
lipoplex
polyplex
continu
make
use
photolabil
compound
block
bioactiv
odn
expos
nearultraviolet
light
intraven
protect
oligonucleotid
degrad
provid
noninvas
sitespecif
deliveri
includ
lipid
deliveri
system
enhanc
transfect
effici
like
liposom
lipoplex
without
surfac
modif
liposom
spheric
vesicl
compos
central
aqueou
compart
enclos
within
phospholipid
bilay
cation
lipid
combin
neutral
lipid
use
formul
liposom
deliv
odn
sirna
intracellularli
neutral
lipid
use
facilit
fusion
cell
membran
cation
lipid
wide
use
formul
cation
liposom
includ
dotap
dotma
howev
lipoplex
along
cation
lipid
contain
anion
amphiphil
molecul
facilit
releas
neg
charg
oligonucleotid
lipoplex
thu
assist
nuclear
local
oligonucleotid
overal
neutral
charg
formul
reduc
biolog
toxic
effect
cation
lipid
lipofectin
rnaifect
oligofectamin
lipofectamin
transit
tko
synthet
cation
cholesterol
natur
analogu
cardiolipin
wide
explor
lipid
improv
deliveri
safeti
efficaci
antisens
drug
thiocholesterolbas
cation
lipid
use
compon
selfassembl
cation
micel
nanolipoparticl
effici
entrap
anion
oligonucleotid
deliv
intracellularli
howev
complex
unstabl
prepar
immedi
use
complex
polym
dna
call
polyplex
amphiphil
block
copolym
spontan
selfassembl
form
core
shelltyp
micel
aqueou
media
call
polymer
micel
solid
core
shell
small
size
modifi
surfac
make
suitabl
carrier
odn
cation
hydrophil
copolym
effici
entrap
anion
oligonucleotid
exampl
copolym
pegblockpolylysin
copolym
pegblockpolyethylenimin
copolym
poli
lacticcoglycolicacid
plgablockpolyarginin
copolym
polymer
nanoaparticul
system
also
report
intracellular
deliveri
odn
proteinac
biopolymerbas
nanoparticl
biocompat
surfac
modifi
improv
transfect
effici
exampl
biopolym
includ
atelocollagen
gelatin
sodium
algin
hyaluron
acid
mani
author
also
report
chitosanbas
nanoparticl
antisens
drug
deliveri
cyclodextrinbas
nanoparticl
also
develop
mark
davi
effici
intracellular
sirna
deliveri
tumor
recent
approv
fda
threecompon
system
compris
cyclodextrincontain
polym
cdp
peg
steric
stabil
agent
human
transferrin
tf
target
ligand
system
report
improv
diseas
state
tumorbear
mice
nanoparticl
inorgan
materi
like
silica
gold
without
surfac
modif
deliv
antisens
drug
intracellularli
also
report
sever
author
lipidpolym
hybrid
system
also
report
deliv
odn
intracellularli
includ
odn
precondens
polyc
coat
either
cation
anion
lipid
amphiphil
polym
without
helper
lipid
polypeptid
pll
protamin
histon
use
precondens
odn
form
polyplex
coat
lipid
layer
form
lipidpolym
hybrid
system
system
also
address
lpd
lipidpolycationdna
system
odn
better
protect
lipidco
polyplex
system
appear
effici
transfect
lipoplex
ex
vivo
equal
activ
vivo
one
approach
deliv
antisens
agent
intracellularli
use
synthet
natur
peptid
system
make
use
small
protein
enzym
receptor
antibodi
complex
antisens
drug
may
provid
sitespecif
deliveri
agent
exampl
peptid
tetraamin
spermin
schiffel
et
al
report
direct
sirna
uptak
tumor
neovasculatur
coupl
integrinbind
rgd
peptid
pegyl
pei
mpg
nmethylpurin
dna
glycosylas
short
amphipath
peptid
util
form
stabl
nanoparticl
effici
cellular
deliveri
sirna
hydrogel
hydrophil
polymer
network
capabl
imbib
larg
amount
water
biolog
fluid
place
aqueou
media
hydrogel
swell
form
insolubl
threedimension
network
via
chemic
crosslink
tiepoint
junction
physic
crosslink
entangl
crystallit
network
compos
either
homopolym
copolym
use
control
drug
releas
reservoirbas
control
releas
system
carrier
swellingcontrol
releas
devic
hydrogel
use
modul
antisens
drug
releas
respons
ph
temperatur
ionic
strength
electr
field
specif
analyt
concentr
differ
thu
make
envirointellig
stimulisensit
deliveri
system
antisens
activ
oligonucleotid
immobil
cation
crosslink
poli
ethylen
oxid
peo
pei
nanogel
evalu
cell
model
poli
methacryl
hydrogel
report
potenti
carrier
odn
also
cation
agarosebas
hydrogel
develop
deliv
odn
target
mrna
prevent
arthriti
anim
model
hydrogel
releas
design
occur
within
specif
area
bodi
eg
within
certain
ph
digest
tract
within
cancer
cell
also
specif
site
use
adhes
cellreceptor
specif
gel
modifi
hydrogel
surfac
inject
odn
physiolog
buffer
local
diseas
site
effect
concentr
site
inject
method
simpl
reproduc
highli
effici
transfect
effici
depend
anatomi
target
organ
inject
volum
inject
rate
nonspecif
hydrodynam
deliveri
use
intracellular
deliveri
watersolubl
compound
small
colloid
particl
even
virus
techniqu
allow
direct
transfer
substanc
cytoplasm
without
endocytosi
hydrodynam
renal
vein
inject
odn
connect
tissu
growth
factor
report
treat
renal
fibrosi
rat
howev
due
larg
inject
volum
invas
techniqu
wide
use
clinic
recent
improv
precis
reproduc
techniqu
report
use
computercontrol
catheterguid
inject
devic
success
gene
deliveri
liver
kidney
muscl
rodent
observ
devic
electropor
techniqu
local
deliveri
odn
make
use
extern
appli
electr
field
increas
electr
conduct
permeabl
cellular
plasma
membran
creat
local
pore
membran
treatment
tissu
hyaluronidas
prior
inject
odn
may
significantli
enhanc
transfect
due
improv
distribut
odn
within
tissu
techniqu
report
success
deliv
phosphorothioatemodifi
odn
cmyc
protooncogen
cell
fluoresceinlabel
odn
promot
protooncogen
cmyb
transderm
howev
techniqu
limit
use
high
cell
mortal
suffer
drawback
difficulti
transfect
cell
larg
area
tissu
due
limit
effect
rang
approxim
cm
electrod
furthermor
surgeri
requir
place
electrod
deepseat
organ
process
paramet
like
voltag
length
number
electr
puls
optim
get
maximum
transfect
minimum
cell
mortal
ultrasoundmedi
antisens
drug
deliveri
noninvas
physic
method
transfect
make
use
ultrasound
wave
optimum
strength
optim
time
facilit
permeat
odn
target
cell
ultrasound
creat
pore
cellular
membran
facilit
passiv
diffus
odn
across
membran
transfect
effici
depend
size
local
concentr
odn
better
transfect
obtain
complex
ond
cation
lipid
use
techniqu
readili
use
sitespecif
deliveri
odn
soft
intern
tissu
method
report
deliv
digoxigeninlabel
odn
treat
prostat
cancer
nude
mice
drawback
associ
ultrasoundmedi
antisens
drug
deliveri
low
transfect
effici
cage
oligonucleotid
one
recent
report
chemic
modifi
odn
target
oligonucleotid
deliveri
monro
et
al
coll
et
al
describ
photocag
spatiotempor
strategi
make
use
photolyt
chromophor
rapid
releas
biolog
activ
substrat
exposur
light
cage
involv
coval
attach
photolabil
compound
effector
nucleic
acid
speci
block
bioactiv
trigger
nearultraviolet
light
photocag
also
protect
effector
nucleic
acid
nucleas
block
nativ
bioactiv
expos
nearultraviolet
light
phenomenon
first
use
kaplan
et
al
releas
induc
biolog
environ
variou
type
cage
compound
commonli
use
effector
nucleic
acid
summar
fig
recent
deiter
group
made
npom
nitropiperonyloxymethyl
cage
dt
phosphoramidit
lightmedi
deliveri
phosphoramidit
oligonucleotid
commerci
avail
addit
deliveri
technolog
discuss
earlier
practic
also
report
includ
use
nonprotein
altern
antibiot
select
neucleotid
bind
aptam
treatment
prostat
cancer
addit
repeat
branch
dendrit
structur
specif
polycation
dendrim
bind
strongli
oligonucleotidessirna
better
nucleas
resist
effici
gene
silenc
also
human
mesenchym
stem
cell
inevit
viabl
nonimmunogen
cellular
deliveri
system
moreov
mani
pharma
compani
licens
fdaapprov
deliveri
platform
special
player
antisens
technolog
market
alzet
pump
minicircl
dna
technolog
platform
print
nanoparticl
technolog
name
tabl
first
step
develop
vector
antisens
drug
deliveri
choos
effect
rout
administr
depend
intend
use
antisens
agent
whether
local
system
potenti
odn
sirna
investig
applic
differ
rout
exampl
skin
lung
mucos
membran
like
intravagin
ocular
nasal
variou
system
deliveri
rout
furthermor
recent
paper
report
studi
sirna
deliveri
oral
rout
target
macrophag
local
deliveri
antisens
drug
electropor
hydrodynam
intraven
inject
reduc
gener
problem
associ
system
administr
exampl
clearanc
bodi
toxic
due
unwant
tissu
distribut
reduc
transfect
due
low
cellular
uptak
suffer
limit
like
cytotox
applic
site
requir
larg
inject
volum
peiassoci
sirna
deliv
via
electropor
rodent
treatment
collageninduc
arthriti
intrathec
inject
antisens
agent
explor
cn
deliveri
number
applic
like
knockdown
serotonin
transport
mice
brain
treatment
variou
diseas
like
chronic
neuropath
pain
formalininduc
nocicept
ocular
diseas
treat
intravitr
inject
antisens
agent
treat
eye
diseas
like
amd
inhibit
ocular
neurovascular
angiogenesi
odn
formul
vitraven
avail
market
treatment
retin
sirna
also
evalu
inhal
therapi
lung
disord
system
applic
moreov
intranas
administr
sirna
investig
rodent
target
heme
enhanc
ischemiareperfusioninduc
lung
apoptosi
treatment
respiratori
viru
infect
howev
mani
diseas
requir
system
administr
henc
special
consider
given
ration
design
antisens
agent
develop
deliveri
vector
discuss
earlier
system
administr
sirna
odn
big
challeng
cross
mani
obstacl
way
target
mani
effort
made
previou
ongo
research
judici
modifi
antisens
agent
develop
effect
formul
desir
applic
therapeut
silenc
variou
endogen
gene
system
administr
deliveri
modifi
sirna
studi
studi
antitumor
activ
protamineantibodymedi
sirna
inject
intraven
intratumor
rodent
sirnatarget
fa
protein
protect
mice
renal
ischemiareperfus
injuri
fulmin
hepat
caspas
sirna
target
liver
via
system
administr
prevent
acut
liver
failur
mice
antisens
technolog
potenti
appli
treat
variou
diseas
especi
viral
infect
cancer
howev
rapid
progress
antisens
technolog
techniqu
found
newer
applic
treat
sever
infect
discuss
detail
odn
wide
use
basic
research
elucid
gener
splice
pattern
variou
gene
turn
may
help
treat
genet
disord
oligonucleotid
splice
specif
intron
premrna
interf
assembl
spliceosom
spliceosom
complex
compris
variou
protein
small
nuclear
rna
snrna
form
splice
event
thu
odn
use
elucid
variou
pathway
involv
synthesi
protein
determin
variou
possibl
mutagen
splice
site
alter
result
inappropri
protein
product
genet
disord
point
mutat
result
new
splice
site
within
intron
direct
splice
machineri
ruptur
splice
pathway
result
format
defect
mrna
inappropri
protein
product
block
splice
site
use
odn
thu
prevent
inappropri
protein
express
howev
oligonucleotid
must
activ
rnase
h
enzym
use
alter
splice
pattern
usual
achiev
induc
certain
chemic
modif
odn
oligonucleotid
rna
duplex
recogn
rnase
h
exampl
enzym
includ
methylphosphon
deriv
oalkyl
oligonucleotid
pna
use
antisens
technolog
oalkyl
oligonucleotid
morpholinooligonucleotid
report
treat
genet
blood
disord
complet
applic
antisens
technolog
investig
protein
function
live
brain
recent
report
technolog
success
use
studi
central
nervou
system
cn
protein
transmembran
receptor
ion
channel
transport
g
protein
growth
factor
mani
belong
larg
famili
close
relat
subtyp
isoform
gener
nondistinguish
use
common
assay
techniqu
use
odn
bind
one
specif
subtyp
howev
possibl
distinguish
suffici
degre
divers
exist
mrna
sequenc
close
relat
protein
phosphodiest
oligonucleotid
exhibit
consider
stabil
cerebrospin
fluid
csf
plasma
requir
frequent
administr
larg
quantiti
obtain
signific
antisens
inhibitori
effect
phosphorothio
oligonucleotid
though
good
stabil
csf
produc
desir
antisens
effect
quit
toxic
odn
exert
inhibitori
effect
rnase
h
mechan
brain
pna
lna
also
tri
inhibit
inappropri
protein
express
odn
readili
cross
bloodbrain
barrier
invas
method
intraventricular
intraparenchym
intrathec
administr
also
tri
deliv
odn
brain
result
tissu
injuri
hemorrhag
antisens
technolog
report
treat
brain
disord
alzheim
diseas
pain
affect
disord
success
select
specif
odn
readili
use
inhibit
express
particular
enzym
receptor
belong
larg
famili
close
relat
subtyp
inhibit
acetyl
cholinesteras
enzym
molecular
target
treatment
diseas
like
alzheim
diseas
myasthenia
gravi
advanc
research
concern
alzheim
diseas
myasthenia
gravi
demonstr
altern
splice
variant
acetyl
cholinesteras
enzym
involv
etiolog
diseas
thu
odn
therapi
could
use
manag
diseas
odn
also
use
success
character
variou
member
dopamin
receptor
technolog
also
employ
differenti
differ
opioid
receptor
viz
mu
delta
kappa
similarli
odn
success
util
studi
variou
phosphatas
involv
cellular
growthcontrol
pathway
thu
help
screen
potenti
anticancer
agent
enzym
regul
divers
cellular
process
metabol
ionchannel
activ
membran
transport
well
learn
memori
thu
inhibit
mani
protein
kinas
use
odn
use
treat
relat
disord
human
inflamm
bodi
protect
respons
physic
microbi
threat
character
red
swell
heat
pain
result
increas
blood
flow
increas
capillari
permeabl
plasma
protein
leakag
migrat
leukocyt
site
injuri
inflamm
deregul
diseas
even
death
happen
acut
inflammatori
process
cell
like
eosinophil
neutrophil
monocyt
macrophag
migrat
site
injuri
respons
chemotact
factor
plateletactiv
factor
leukotrien
cytokin
inflamm
antisens
technolog
use
demonstr
rel
import
variou
signal
compon
molecular
level
control
manner
henc
technolog
use
defin
role
particular
mediat
process
inflamm
screen
potenti
antiinflammatori
drug
technolog
report
downregul
success
molecular
target
involv
variou
inflammatori
diseas
crohn
diseas
inflammatori
bowel
diseas
renal
allograft
reject
psoriasi
treatment
variou
diseas
respiratori
tract
novel
respir
antisens
drug
call
rason
use
rason
deliv
antisens
medicin
effect
safe
even
deep
lung
interact
uniqu
pulmonari
surfact
alveolar
epitheli
cell
result
enhanc
cellular
uptak
oligonucleotid
effect
even
low
dose
deliv
use
deliveri
devic
whether
nebul
dri
powder
inhal
meter
dose
inhal
rason
success
use
treat
respiratori
diseas
asthma
influenza
bronchiti
pulmonari
fibrosi
pneumonia
lung
cancer
numer
antisens
drug
current
investig
treat
variou
cancer
human
odn
addit
advantag
less
toxic
convent
anticancer
medicin
combin
therapi
antisens
drug
convent
medic
may
result
reduct
dose
doserel
side
effect
therapi
phosphorothio
first
odn
use
combin
cisplatin
treatment
bladder
cancer
sinc
sever
antisens
drug
investig
variou
cancer
like
colon
cancer
lymphat
leukemia
lung
cancer
testicular
cancer
lymphoma
odn
use
target
specif
compon
blood
vessel
wall
influenc
pathophysiolog
mechan
renal
cardiovascular
disord
sever
report
document
role
tissu
kallikreinkinin
system
pathogenesi
hypertens
reduc
urinari
kallikrein
observ
hypertens
subject
henc
system
deliveri
human
tissu
kallikrein
gene
result
decreas
blood
pressur
may
assuag
even
glomerular
sclerosi
howev
antisens
technolog
success
use
elucid
role
tissu
kallikreinkinin
system
blood
pressur
regul
intracerebroventricular
inject
odn
kininogen
mrna
bradykinin
b
receptor
mrna
result
increas
blood
pressur
howev
inject
antisens
b
receptor
caus
decreas
blood
pressur
thu
antisens
technolog
use
elucid
role
bradykinin
b
b
receptor
central
regul
blood
pressur
alway
difficult
design
develop
antivir
drug
low
toxic
improv
specif
ration
strategi
fight
viral
diseas
inhibit
gene
implic
variou
viral
infect
help
odn
antisens
technolog
easili
appli
virus
encod
uniqu
protein
differ
one
encod
normal
cell
vitraven
fomivirsen
first
antivir
odn
use
intravitr
treat
cytomegaloviru
retin
variou
virus
investig
potenti
target
antisens
drug
includ
human
papillomaviru
human
immunodefici
hepatitisb
viru
influenza
viru
herp
simplex
viru
hsv
tradit
antivir
drug
competit
antagonist
bind
diseasecaus
protein
subsequ
block
action
natur
agonist
result
toxicolog
manifest
viral
protein
essenti
replic
virus
prime
target
antisens
drug
odn
select
specif
readili
bind
target
mrna
sequenc
therebi
downregul
express
relat
protein
caus
death
viru
antisens
molecul
mediat
rnai
synthes
chemic
laboratori
introduc
cell
achiev
target
gene
silenc
open
enorm
possibl
use
potenti
drug
candid
follow
key
featur
highlight
advantag
antisens
technolog
specif
sirna
l
sirna
potent
highli
specif
therapeut
moieti
l
tradit
drug
limit
target
wherea
due
complet
human
genom
project
antisens
agent
like
sirna
design
unlimit
diseas
target
l
drug
act
symptomat
relief
diseas
inhibit
diseasecaus
factor
howev
sirna
therapi
allow
format
diseasecaus
element
henc
act
remov
root
caus
diseas
l
sirna
explor
prophylact
agent
variou
known
epidem
diseas
l
antisens
technolog
util
prevent
treatment
deadli
diseas
like
saar
swine
flu
sequencespecif
design
complementari
diseasecaus
gene
virus
l
diseas
caus
mutat
singl
allel
gene
sirna
design
act
particular
allel
without
affect
normal
allel
l
difficulti
treat
viral
diseas
like
hiv
chang
viral
mutat
thu
drug
effect
particular
time
effect
next
viral
mutat
sirna
design
accord
particular
gene
mutat
moreov
pool
one
mutantspecif
sirna
incorpor
singl
deliveri
agent
deliv
one
time
l
carrier
approv
sirna
deliveri
differ
mutantspecif
sirna
formul
without
chang
carrier
system
l
cancerlik
diseas
highli
patient
specif
thu
sirna
explor
person
therapi
benefit
individu
patient
l
antisens
drug
potenti
act
chemosensit
agent
prevent
multidrug
resist
block
resistancecaus
compon
three
decad
antisens
research
date
two
antisens
agent
approv
regulatori
bodi
local
applic
howev
larg
number
diseas
requir
system
administr
desir
applic
intens
research
progress
make
agent
avail
market
system
use
leader
antisens
technolog
learn
reason
unsuccess
entri
clinic
drawback
product
like
bevasiranib
despit
up
down
sirna
product
odn
ribozym
aptam
gain
entri
clinic
studi
other
still
preclin
stage
although
fda
yet
issu
guidelin
target
deliveri
sirna
sever
pharmaceut
biotechnologybas
compani
involv
develop
sirna
deliveri
techniqu
laid
intern
specif
maxim
reliabl
guidelin
valid
design
process
evalu
sirna
formul
present
rule
convent
base
practic
understand
sirna
design
deliveri
perform
follow
develop
antisens
formul
order
achiev
regulatori
approv
gain
entri
antisens
therapeut
market
present
mani
comput
softwar
program
optimum
select
rule
avail
specif
sirna
design
sirna
design
excel
specif
target
mrna
requir
chemic
stabil
pharmacolog
effect
ration
sirna
design
scheme
develop
base
understand
rnai
biochemistri
natur
occur
mirna
function
differ
thermodynam
stabil
two
strand
sirna
determin
strand
direct
toward
risc
taken
consider
design
sirna
sever
sirna
shrna
give
phenotyp
outcom
similar
offtarget
effect
achiev
pool
differ
trigger
critic
correl
phenotyp
outcom
effect
suppress
examin
target
protein
level
help
determin
effect
sirna
pool
sever
sirna
shrna
moreov
sirna
shrna
affect
target
protein
act
neg
control
arguabl
one
could
use
scrambl
sirna
shrna
purpos
better
use
scrambl
sirna
known
enter
rnai
pathway
effect
without
biolog
activ
exampl
targetvalid
rna
rnatarget
luciferas
green
fluoresc
protein
marker
gene
sirna
effect
depend
specif
toward
risc
enzym
complex
specif
affect
high
enzymetosubstr
ratio
thu
sirna
concentr
titrat
correl
degre
suppress
phenotyp
outcom
fact
suppress
express
observ
sirna
exampl
hela
cell
low
concentr
pm
besid
design
sirna
cocktail
sirna
formul
modifi
conjug
complex
deliveri
carrier
must
meet
criteria
ensur
reproduc
reassembl
function
complex
incorpor
effici
zeta
potenti
polydispers
aggreg
mousehuman
serum
chemic
stabil
data
assembl
day
provid
confid
formul
final
effect
formul
predict
basi
specif
design
particular
formul
augment
triumph
final
formul
mani
compani
like
sirna
therapeut
reveal
specif
explicitli
state
greater
reduct
target
mrna
level
target
sirna
concentr
nm
media
contain
serum
control
sirna
concentr
nm
media
contain
serum
reduc
target
mrna
level
less
fivefold
window
ic
target
gene
silenc
ic
reduct
viabil
activ
deliveri
system
report
least
three
cell
line
relev
deliveri
system
evalu
target
moieti
deliveri
platform
valid
target
use
cell
line
differenti
express
target
receptor
use
assembl
activ
inact
mutant
target
moieti
vivo
perform
sirnacontain
deliveri
assembl
evalu
suitabl
anim
model
comparison
singl
intraven
dose
mgkg
target
sirnacontain
deliveri
assembl
control
provid
deliveri
platform
target
moeiti
well
assembl
incorpor
inactivemut
target
moieti
evalu
provid
evid
effect
target
reduct
target
mrna
level
target
tissu
mgkg
dose
target
sirna
h
less
reduct
target
mrna
level
target
tissu
mgkg
dose
control
sirna
h
demonstr
rnaiinduc
offtarget
effect
less
cytokin
induct
h
mgkg
less
increas
alt
ast
mgkg
effect
bodi
weight
blood
clinic
chemistri
hematolog
data
h
also
essenti
prior
understand
natur
target
mechan
passiv
activ
help
prove
activ
target
cellular
intern
vitro
block
appropri
solubl
ligand
receptor
incorpor
target
moeiti
abl
compet
ligand
like
transferrin
folat
galactosamin
bind
target
cell
control
vivo
activ
target
experi
includ
nonfunct
target
moieti
similar
class
molecular
weight
pi
like
irrelev
igg
materi
without
control
target
ligand
good
control
addit
unrel
cell
line
express
receptor
good
control
least
fivefold
greater
vivo
gene
silenc
target
cell
use
activ
target
materi
observ
neg
target
control
mark
astonish
potenti
antisens
technolog
surg
number
patent
appli
past
year
must
take
account
grant
us
patent
us
applic
sirna
year
trend
patent
toward
gene
silenc
prepar
techniqu
judici
design
modif
improv
specif
nucleas
resist
transfect
effici
target
molecul
present
focu
antisens
research
toward
deliv
adequ
amount
right
cell
right
time
appropri
sirna
design
label
suitabl
deliveri
system
commerci
benefit
fulli
exploit
sensibl
execut
patent
strategi
base
understand
exist
patent
coverag
mani
antisens
technologybas
formul
develop
view
toward
patent
usa
key
differ
us
intern
patent
system
may
relev
intern
patent
rnai
technolog
patent
recent
antisens
technolog
base
sirna
grasp
analyz
strength
weak
patent
establish
technolog
monoclon
antibodi
gene
therapi
odn
success
patent
posit
also
address
therapeut
characterist
platform
technolog
antisens
technolog
treatment
variou
disord
like
allergi
ocular
angiogenesi
cancer
cardiovascular
problem
cn
disord
aid
well
patent
target
deliveri
technolog
like
nanoparticl
polym
lipid
base
electroporationbas
deliveri
carrier
mediateddeliveri
biodegrad
cation
polymerbas
deliveri
other
explor
glanc
us
patent
scenario
major
compani
involv
sirna
technolog
present
tabl
antisens
therapeut
though
explor
tremend
number
diseas
disord
bias
toward
anticanc
therapeut
due
differ
normal
tumor
vasculatur
highest
concentr
achiev
around
tumor
vasculatur
thu
target
gene
within
endotheli
support
cell
becom
attract
antitumor
strategi
moreov
applic
liposom
technolog
also
explor
field
cancer
vaccin
coher
util
liposom
antisens
agent
thu
becom
hot
area
mani
lead
compani
involv
rnai
therapeut
fact
liposom
polyconjug
biodegrad
polymer
carrier
emerg
lead
platform
system
deliveri
rnai
therapeut
offer
consider
promis
diseas
liver
solid
cancer
well
potenti
enhanc
vaccin
infecti
diseas
immun
cellrel
disord
drug
base
liposom
biodegrad
polymer
carrier
system
alreadi
market
big
leap
forward
occur
toward
develop
polymerand
liposomebas
rnai
formul
make
swift
safer
dosag
form
regulatori
perspect
attent
toward
develop
attract
feasibl
field
rnaibas
vaccin
also
need
hour
mani
flu
vaccin
like
sever
acut
respiratori
syndrom
sar
swine
flu
mutat
varieti
develop
put
one
pool
cover
closer
probabl
mutat
exist
mutant
varieti
singl
formul
antisens
formul
potenti
side
effect
lose
viabil
biolog
milieu
extens
satisfactori
pharmacolog
toxicolog
studi
perform
initi
develop
preclin
stage
avoid
failur
later
clinic
phase
mani
experi
evalu
alreadi
perform
eldest
antisens
technolog
oligonucleotid
thu
shortcom
profit
studi
taken
account
develop
newer
antisensebas
formul
highli
specif
agent
like
sirna
boom
agent
individu
therapi
princip
compani
activ
involv
rnaibas
therapeut
focu
invest
develop
person
therapeut
agent
patient
suffer
either
major
disord
rare
one
occur
individualspecif
gene
defect
mutat
potent
agent
effect
low
dose
sirna
strikingli
suitabl
agent
deliv
via
inhal
rout
also
mani
studi
done
inhal
variou
gene
support
develop
stabl
effect
aerosoliz
nebuliz
sirna
formul
simplic
sirna
design
specif
potenc
avail
human
genom
inform
feasibl
fabric
requir
sequenc
applic
endless
number
diseaserel
express
offer
broadest
applic
almost
everi
area
therapeut
thu
featur
sincer
evalu
special
distribut
antisenseori
research
variou
respect
compani
industri
institut
request
requir
collabor
cooper
support
one
anoth
order
present
longawait
technolog
practic
avail
therapi
humankind
